PMPéter Mátyus

Péter Mátyus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Péter Mátyus has a total of 534 co-authors. Here are the top co-authors by number of shared publications:

  • Petra Dunkel

    Institute of Organic Chemistry, Semmelweis University, 1092 Budapest, Hungary

    12 shared publications
  • Balázs Balogh

    Department of Organic Chemistry, Semmelweis University, Hőgyes u. 7., 1092 Budapest, Hungary, Fax: +36 1 217-0851

    11 shared publications
  • Pál Tapolcsányi

    Department of Organic Chemistry, Semmelweis University, H-1092 Budapest, Hőgyes E. u. 7., Hungary

    10 shared publications
  • György Hajós

    Institute of Biomolecular Chemistry, Chemical Research Center, Hungarian Academy of Sciences, Pusztaszeri ut 59, H-1025 Budapest, Hungary

    9 shared publications
  • Katrien Monsieurs

    9 shared publications
  • Zsuzsanna Riedl

    Institute of Biomolecular Chemistry, Chemical Research Center, Hungarian Academy of Sciences, Pusztaszeri ut 59, H-1025 Budapest, Hungary

    9 shared publications

Latest Publications

  • Open Access

    Preclinical and Phase I Clinical Development of a Novel Multi-target Drug Candidate for Neuropathic Pain

    by Zsuzsanna Helyes, Adam Horvath Horvath, Nikolett Szentes, Valeria Tekus, Szilard Pal, Tamás Kálai, Péter Mátyus

    ID 16166 Poster Board 293 SZV-1287 (3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime) is a unique, novel multi-target drug, which irreversibly inhibits the semicarbazide-sensitive amine oxidase (ssAO) enzyme. ssAO metabolizes primary amines to irritants like methyglyoxal and formaldehyde activating the transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) non-selective cation channels. SZV-1287 also directly antagonizes TRPA1 and TRPV1 receptors located predominantly on nociceptive primary sensory neurons, immune cells and several central nervous system regions. Furthermore, its main metabolite, oxaprozin, is a clinically used cyclooxygenase inhibitor, which might have synergistic effect with the mother compound in several pain conditions. We provided proof-of-concept for the ability of single SZV-1287 administration (10-50 mg/kg i.p.) to significantly reduce acute and chronic pain behaviors including the sciatic nerve injury-induced neuropathic hyperalgesia in mice via inhibiting TRPA1 and TRPV1 activation. Repeated 20 mg/kg SZV-1287 injections attenuated chronic arthritis (edema, myeloperoxidase activity, histopathological changes) and related hyperalgesia, L4-L6 spinal dorsal horn neuroinflammation (microgliosis) even in the late phase of the model when neuropathic mechanisms are important. Since under the acidic conditions of the stomach, SZV-1287 is transformed to oxaprozin, which is ineffective for neuropathic pain, enterosolvent capsule was formulated and tested during the preclinical development. SZV-1287 was quickly absorbed, its plasma concentration was stable for 2 h, and entered the brain. Although SZV-1287 significantly decreased proton-induced TRPV1-mediated calcium-influx potentially leading to hyperthermia, it did not alter the deep body temperature. It did not induce any considerable toxicity either in rodents or in dogs. After the approval of the preclinical dossier by the Hungarian authority, the phase IA trial (single ascending dosing: 75, 150, 300, 450 mg) has successfully been completed without any considerable side effects. SZV-1287 plasma concentration was stable for 4 h and oxaprozin concentration continously increased during 24 h. If the candidate proves to be safe in humans after repeated dosing for 7 days with favorable kinetic profile, the compound can progress to the phase II. studies in neuropathic pain patients. This project is a good example for successful early development of a novel compound originating from the academia together with industrial partners. Support/Funding Information: GINOP-2.2.1-15-2016-00020, Eotvos Lorand Research Network, OTKA-K138046, National Laboratory for Drug Research and Development, TKP2021-EGA-16, National Brain Research Program-3

  • Analgesic effects of the novel semicarbazide-sensitive amine oxidase inhibitor SZV 1287 in mouse pain models with neuropathic mechanisms: Involvement of transient receptor potential vanilloid 1 and ankyrin 1 receptors

    by Ádám Horváth, Valéria Tékus, Noémi Bencze, Nikolett Szentes, Bálint Scheich, Kata Bölcskei, Éva Szőke, Attila Mócsai, Éva Tóth-Sarudy, Péter Mátyus, et al.


  • Open Access

    Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease

    by Mária Baranyi, Pier Francesca Porceddu, Flóra Gölöncsér, Szabina Kulcsár, Lilla Otrokocsi, Ágnes Kittel, Annalisa Pinna, Lucia Frau, Paul B. Huleatt, Mui-Ling Khoo, et al.

    Mitochondrial dysfunction, oxidative stress and their interplay are core pathological features of Parkinson’s disease. In dopaminergic neurons, monoamines and their metabolites provide an additional source of reactive free radicals during their breakdown by monoamine oxidase or auto-oxidation. Moreover, mitochondrial dysfunction and oxidative stress have a supraadditive impact on the pathological, cytoplasmic accumulation of dopamine and its subsequent release. Here we report the effects of a novel series of potent and selective MAO-B inhibitory (hetero)arylalkenylpropargylamine compounds having protective properties against the supraadditive effect of mitochondrial dysfunction and oxidative stress. The (hetero)arylalkenylpropargylamines were tested in vitro, on acute rat striatal slices, pretreated with the complex I inhibitor rotenone and in vivo, using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced acute, subchronic, and chronic experimental models of Parkinson’s disease in mice. The compounds exhibited consistent protective effects against i) in vitro oxidative stress induced pathological dopamine release and the formation of toxic dopamine quinone in the rat striatum and rescued tyrosine hydroxylase positive neurons in the substantia nigra after rotenone treatment; ii) in vivo MPTP-induced striatal dopamine depletion and motor dysfunction in mice using acute and subchronic, delayed application protocols. One compound (SZV558) was also examined and proved to be protective in a chronic mouse model of MPTP plus probenecid (MPTPp) administration, which induces a progressive loss of nigrostriatal dopaminergic neurons. Simultaneous inhibition of MAO-B and oxidative stress induced pathological dopamine release by the novel propargylamines is protective in animal models and seems a plausible strategy to combat Parkinson’s disease.


  • One Size Does Not Fit All: Challenging Some Dogmas and Taboos in Drug Discovery

    by Christina Ll Chai, Péter Mátyus

    Advances in genetics, biology, chemical synthesis and computational methods have contributed to the understanding of diseases and drugs and with all of the above, there is an expectation that we are in a better position than ever before to create effective medicines for our needs. The reality is, however, disconnected from the expectation – US FDA drug approval statistics show that the number of approved drugs, especially the first-in-class drugs, is not commensurate with our improved knowledge. In this perspective, we offer our views on the possible reasons for this, focusing on small-molecule drugs and suggest some ideas for further considerations.


  • Open Access

    Biomarkerek hálózatától a klinikai döntéstámogatásig

    by Péter Antal, József Reiter, Péter Mátyus

    The rapidly accumulating, heterogeneous, numerous biomedical data and the increasing knowledge represent both the key areas and the major bottleneck in the complete realization of personalized medicine. Traditional clinical aims as well as decision-making processes in drug research need systems-based integration of data and their analyses, which require a wide range of new mathematical approaches and application of information technologies. In the world of biomarkers, all such tasks correspond to three types of biomarkers, namely, endpoint, target and diagnostic biomarkers, which together form a complex network. To decipher the networks, probabilistic graphical models are introduced. Briefly, the authors illustrate their use for exploration and visualization of direct dependencies among biomarkers. Finally, construction of decision networks and their application to structural and quantitative optimization of biomarkers are discussed to provide a novel type of supporting tools for clinical practice. Orv. Hetil., 2015, 156(51), 2077–2081.

  • Metabolism‐Activated Multitargeting (MAMUT): An Innovative Multitargeting Approach to Drug Design and Development

    by Péter Mátyus, Christina L. L. Chai

    Multitargeting is a valuable concept in drug design for the development of effective drugs for the treatment of multifactorial diseases. This concept has most frequently been realized by incorporating two or more pharmacophores into a single hybrid molecule. Many such hybrids, due to the increased molecular size, exhibit unfavorable physicochemical properties leading to adverse effects and/or an inappropriate ADME (absorption, distribution, metabolism, and excretion) profile. To avoid this limitation and achieve additional therapeutic benefits, here we describe a novel multitargeting strategy based on the synergistic effects of a parent drug and its active metabolite(s). The concept of metabolism-activated multitargeting (MAMUT) is illustrated using a number of examples.


  • Some Operational Characteristics of Glycine Release in Rat Retina: The Role of Reverse Mode Operation of Glycine Transporter Type-1 (GlyT-1) in Ischemic Conditions

    by Adrienn Hanuska, Gábor Szénási, Mihaly Albert, Laszlo Koles, Agoston Varga, Andras Szabo, Peter Matyus, Laszlo G. Harsing

    Rat posterior eyecups containing the retina were prepared, loaded with [3H]glycine and superfused in order to determine its release originated from glycinergic amacrine cells and/or glial cells. Deprivation of oxygen and glucose from the Krebs-bicarbonate buffer used for superfusion evoked a marked increase of [3H]glycine release, an effect that was found to be external Ca2+-independent. Whereas oxygen and glucose deprivation increased [3H]glycine release, its uptake was reduced suggesting that energy deficiency shifts glycine transporter type-1 operation from normal to reverse mode. The increased release of [3H]glycine evoked by oxygen and glucose deprivation was suspended by addition of the non-competitive glycine transporter type-1 inhibitor NFPS and the competitive inhibitor ACPPB further suggesting the involvement of this transporter in the mediation of [3H]glycine release. Oxygen and glucose deprivation also evoked [3H]glutamate release from rat retina and the concomitantly occurring release of the NMDA receptor agonist glutamate and the coagonist glycine makes NMDA receptor pathological overstimulation possible in hypoxic conditions. [3H]Glutamate release was suspended by addition of the excitatory amino acid transporter inhibitor TBOA. Sarcosine, a substrate inhibitor of glycine transporter type-1, also increased [3H]glycine release probably by heteroexchange shifting transporter operation into reverse mode. This effect of sarcosine was also external Ca2+-independent and could be suspended by NFPS. Energy deficiency in retina induced by ouabain, an inhibitor of the Na+–K+-dependent ATPase, and by rotenone, a mitochondrial complex I inhibitor added with the glycolytic inhibitor 2-deoxy-d-glucose, led to increase of retinal [3H]glycine efflux. These effects of ouabain and rotenone/2-deoxy-d-glucose could also be blocked by NFPS pointed to the preferential reverse mode operation of glycine transporter type-1 as a consequence of impaired cellular energy homeostasis. Immunohistochemical studies revealed that glycine transporter type-1, of which reverse mode operation assures [3H]glycine release, is expressed in amacrine cells in the inner nuclear and plexiform layers of the retina and also in Müller macroglia cells. We conclude that disruption of the balanced normal/reverse mode operation of glycine transporter type-1 is likely a significant factor contributing to neurotoxic processes of the retina. The possibility to inhibit glycine transporter type-1 mediated glycine efflux by drugs more potently than glycine uptake might offer some therapeutic potential for the treatment of various neurodegenerative disorders of the retina.


  • Analysis of Edg-Like LPA Receptor-Ligand Interactions

    by Balazs Balogh, Tamas Pazmany, Peter Matyus

    The phospholipid derivative lysophosphatidic acid (LPA) serves as a signalling molecule through the activation of LPA receptors, which belong to the G-protein-coupled receptors. From a pharmacological point of view, the (‘EDG-like’) LPA1-3 receptors have attracted much attention, therefore we have also been focusing in our study on these subtypes. The LPA1receptors are widely expressed in the human body; interestingly, LPA1 might have a role in the pathomechanism of obesity. In order to recognize key structural features of the molecular interactions of human LPA1with its agonists, we built up the 3D structure of the LPA1 through homology modeling. Next, LPA1 agonists and antagonists were docked into the model. The mode of binding and the interactions between ligands and key amino acids (R3.28 and Q3.29) were consistent with mutagenesis assays and previously published models, indicating that this model is able to discriminate high-affinity compounds and may be useful for the development of novel agonists of LPA1. Homology models were also constructed for LPA2 and LPA3. All available agonists with published EC50 values, antagonists with IC50 values and compounds with Ki values for either of LPA1, LPA2 or LPA3 were collected from the ChEMBL database and were docked into the corresponding model.Ourmodels for the LPA1-3 receptors can discriminate high-affinity compounds identified in silico HTS studies and may be useful for the development of novel agonistsof LPA receptors. With a better understanding of the differences between LPA1-3 receptors new, selective agonists and antagonist could be designed, which could be used in the therapy of various diseases with a better side-effect profile.


  • Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms

    by Laszlo G. Harsing Jr., Julia Timar, Geza Szabo, Szabolcs Udvari, Katalin M. Nagy, Bernadett Marko, Gabriella Zsilla, Andrea Czompa, Pal Tapolcsanyi, Akos Kocsis, et al.

    We have synthesized a novel series of N-substituted sarcosines, analogues of NFPS (N-[3-(biphenyl-4- yloxy)-3-(4-fluorophenyl)propyl]-N-methylglycine), as type-1 glycine transporter (GlyT-1) inhibitors. Several compounds incorporated a diazine ring inhibited recombinant hGlyT-1b expressed permanently in CHO cells and GlyT-1 in rat brain synaptosomal preparations. A structure-activity relationship for the newly synthesized compounds was obtained and discussed on the ground of their GlyT-1 inhibitory potencies. Replacement of the biphenyl-4-yloxy moiety in NFPS with a 5-pyridazinylphenoxy moiety (compounds 3, 4, 5, and 6) or a 2-phenyl-5- pyridazinyloxy moiety (compounds 10, 11, and 12) afforded compounds exhibiting potent inhibition on GlyT-1 activity. The GlyT-1 inhibitory properties of NFPS analogues, in which sarcosine was closed into a ring forming (methylamino)pyridazine-3-(2H)-one, were markedly reduced (compounds 13 and 14). The pyridazine-containing GlyT-1 inhibitors with in vitro GlyT-1 inhibitory potency also enhanced extracellular glycine concentrations in conscious rat striatum as was measured by microdialysis technique. In contrast to NFPS, sarcosine-based pyridazine containing GlyT-1 inhibitors failed to evoke compulsive running behavior whereas they inhibited phencyclidine- induced hypermotility in mice. It is believed that increase of extracellular concentrations of glycine by inhibition of its reuptake may probably influence positively glutamate N-methyl-D-aspartate (NMDA)-type ionotropic receptors in the central nervous system. This may have importance in the treatment of neuropsychiatric disorders associated with hypofunctional NMDA receptor-mediated glutamatergic neurochemical transmission. Thus, impaired NMDA receptor functions have been shown to be involved in the development of the negative symptoms and the cognitive deficit of schizophrenia and the treatment of these symptoms is the possible clinical indication of GlyT-1 inhibitors including those containing pyridazine moiety.